Differential expression of Cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Molina Ortiz, Dora ^a   Camacho Carranza, Rafael ^b   González Zamora, José Francisco ^a   Shalkow Kalincovstein, Jaime ^c   Cárdenas Cardós, Rocío ^a   Ností Palacios, Rosario ^a   Vences Mejía, Araceli ^a  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Ctro Nac para la Prevencion y el Tratamiento del Cancer en la Infancia y la Adolescencia (CeNSIA)   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2E1; CYTOCHROME P450 2W1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MESSENGER RNA; UNCLASSIFIED DRUG; CYP1A1 PROTEIN, HUMAN; CYP1A2 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN; CYP2W1 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; TUMOR MARKER;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYP1A1 GENE; CYP1A2 GENE; CYP1B1 GENE; CYP2E1 GENE; CYP2W1 GENE; CYP3A4 GENE; CYP3A5 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MALE; PRESCHOOL CHILD; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SCHOOL CHILD; TISSUE DISTRIBUTION; UPREGULATION; WESTERN BLOTTING; COMPARATIVE STUDY; FOLLOW UP; GENETICS; INFANT; METABOLISM; PROSPECTIVE STUDY; SKELETAL MUSCLE;

ADOLESCENT; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP1B1; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; MUSCLE, SKELETAL; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84899451281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093261     Document Type: Article

References (32)

1. Saab R, Spunt SL, Skapek SX (2011) Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol 94: 197-234.
2. Wang C (2012) Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res 91: 341-350.
3. Grufferman S, Wang HH, DeLong ER, Kimm SY, Delzell ES, et al. (1982) Environmental factors in the etiology of rhabdomyosarcoma in childhood. J Natl Cancer Inst 68: 107-113. (Pubitemid 12167071)
4. Hartley AL, Birch JM, McKinney PA, Teare MD, Blair V, et al. (1988) The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): case control study of children with bone and soft tissue sarcomas. Br J Cancer 58: 838-842. (Pubitemid 19033408)
5. Pappo AS, Shapiro DN, Crist WM, Maurer HM (1995) Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13: 2123-2139.
6. Melguizo C, Prados J, Rama AR, Ortiz R, Álvarez PJ, Fernández JE, et al. (2001) Multidrug resistance and rhabdomyosarcoma. Oncol Rep 26: 755-761.
7. Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7: 3193-3198. (Pubitemid 32963843)
8. McFadyen MC, Melvin WT, Murray GI (2004) Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3: 363-371. (Pubitemid 39193712)
9. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, et al. (2004) Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 19: 1967-1976. (Pubitemid 38918646)
10. Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155-1162. (Pubitemid 35246494)
11. Pavek P, Dvorak Z (2008) Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9: 129-143. (Pubitemid 351461002)
12. Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43: 149-173. (Pubitemid 37372638)
13. Rodriguez AC, Ingelman SM (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25: 1679-1691.
14. Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, et al. (2013) Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 31: 3226-32.
15. Androutsopoulos VP, Tsatsakis AM, Spandidos DA (2009) Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 9: 187-203.
16. Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35: 307-340.
17. Molina OD, González ZJF, Camacho CR, López AO, Colin MO, et al. (2013) Xenobiotic-Metabolizing Enzymes in Skeletal Muscle of Children and Adolescents. Pharmacology & Pharmacy 4: 231-239.
18. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, et al. (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026-3031. (Pubitemid 27315056)
19. Murray GI, Melvin WT, Greenlee WF, Burke MD (2001) Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297-316. (Pubitemid 32390115)
20. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J Pharmacol Exp Ther 296: 537-41. (Pubitemid 32112483)
21. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, et al. (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778. (Pubitemid 34250822)
22. Bergheim I, Bode C, Parlesak A (2005) Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol 5: 34-44.
23. Kocarek TA, Zangar RC, Novak RF (2000) Post-transcriptional regulation of rat CYP2E1 expression: role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Arch Biochem Biophys 376: 180-190. (Pubitemid 30205128)
24. Tanaka E, Terada M, and Misawa S (2000) Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 25: 165-175. (Pubitemid 30495308)
25. Karlgren M, Miura S, Ingelman-Sundberg M (2005) Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol 207: 57-61.
26. Karlgren M, Ingelman-Sundberg M (2007) Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin Ther Targets 11: 61-67.
27. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, et al. (2007) Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8: 1315-1325. (Pubitemid 350162848)
28. Trédan O, Garbens AB, Lalani AS, Tannock IF (2009) The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 69: 940-947.
29. Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, et al. (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21: 2481-2485. (Pubitemid 46606328)
30. Mir O, Ropert S, Alexandre J, Goldwasser F, Treluyer JM (2007) CYP3A4/5 and pharmacogenetics in patients with sarcoma. Lancet Oncol 8: 667-668. (Pubitemid 47163581)
31. Chang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637. (Pubitemid 23360263)
32. Martínez C, García-Martín E, Pizarro RM, García-Gamito FJ, Agúndez JA (2002) Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87: 681-686.